The high-affinity CTLA4-Ig, belatacept, currently approved for use in kidney transplant recipients (43) inhibits CD28 costimulation, a critical pathway for Tconv cell activation as well as Treg cell development and homeostasis. The gene discussed is CD28; the disease is kidney transplant.